{
  "id": "61f939a5882a024a1000004a",
  "type": "yesno",
  "question": "Is tivantinib effective for MET-high hepatocellular carcinoma?",
  "ideal_answer": "No. In phase 3 clinical trials Tivantinib did not improve overall survival compared with placebo in patients with MET-high hepatocellular carcinoma despite promising phase 2 trial results.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29625879",
    "http://www.ncbi.nlm.nih.gov/pubmed/30190953",
    "http://www.ncbi.nlm.nih.gov/pubmed/32716114",
    "http://www.ncbi.nlm.nih.gov/pubmed/23167786"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Tivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafenib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "At a median follow-up of 18\u00b71 months (IQR 14\u00b71-23\u00b71), median overall survival was 8\u00b74 months (95% CI 6\u00b78-10\u00b70) in the tivantinib group and 9\u00b71 months (7\u00b73-10\u00b74) in the placebo group (hazard ratio 0\u00b797; 95% CI 0\u00b775-1\u00b725; p=0\u00b781).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In Phase I and II studies, tivantinib (ARQ 197), an oral inhibitor of MET, demonstrated promising antitumor activity in patients with HCC, both as monotherapy and in combination with sorafenib. A randomized Phase II trial in second-line HCC showed improved overall survival (hazard ratio: 0.38; p = 0.01) in patients with MET-high tumors, as demonstrated by immunohistochemistry, treated with tivantinib versus placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30190953",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32716114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Median progression-free survival was 2.8 (95% confidence interval: 2.7-2.9) and 2.3 (1.5-2.8) mo in the tivantinib and placebo groups, respectively (hazard ratio\u00a0=\u00a00.74, 95% confidence interval: 0.52-1.04, P\u00a0=\u00a0.082). Median overall survival was 10.3 (95% confidence interval: 8.1-11.6) and 8.5 (6.2-11.4) mo in the tivantinib and placebo group, respectively (hazard ratio\u00a0=\u00a00.82, 95% confidence interval: 0.58-1.15). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32716114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32716114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32716114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Tivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafeni",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated wit",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ostic factor in HCC after sorafenib failure. Tivantinib demonstrated a nearly doubling of progression free and overall survival in the MET high group compared to placebo in a Phase II study in patient",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23167786",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}